Zhao Peng, Yang Liping, Li Jiansheng, Li Ya, Tian Yange, Li Suyun
Key Laboratory of Chinese Internal Medicine, Henan University of Traditional Chinese Medicine, Zhengzhou, People's Republic of China; Collaborative Innovation Center for Respiratory Disease Diagnosis and Treatment and Chinese Medicine Development of Henan Province, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, People's Republic of China.
Collaborative Innovation Center for Respiratory Disease Diagnosis and Treatment and Chinese Medicine Development of Henan Province, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, People's Republic of China; Department of Respiratory Diseases, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, People's Republic of China.
Int J Chron Obstruct Pulmon Dis. 2016 Mar 15;11:553-66. doi: 10.2147/COPD.S100352. eCollection 2016.
Bufei Jianpi formula (BJF) has long been used as a therapeutic agent in the treatment of COPD. Systems pharmacology identified 145 active compounds and 175 potential targets of BJF in a previous study. Additionally, BJF was previously shown to effectively prevent COPD and its comorbidities, such as ventricular hypertrophy, by inhibition of inflammatory cytokine production, matrix metalloproteinases expression, and other cytokine production, in vivo. However, the system-level mechanism of BJF for the treatment of COPD is still unclear. The aim of this study was to gain insight into its system-level mechanisms by integrating transcriptomics, proteomics, and metabolomics together with systems pharmacology datasets. Using molecular function, pathway, and network analyses, the genes and proteins regulated in COPD rats and BJF-treated rats could be mainly attributed to oxidoreductase activity, antioxidant activity, focal adhesion, tight junction, or adherens junction. Furthermore, a comprehensive analysis of systems pharmacology, transcript, protein, and metabolite datasets is performed. The results showed that a number of genes, proteins, metabolites regulated in BJF-treated rats and potential target proteins of BJF were involved in lipid metabolism, cell junction, oxidative stress, and inflammatory response, which might be the system-level therapeutic mechanism of BJF treatment.
补肺健脾方（BJF）长期以来一直被用作治疗慢性阻塞性肺疾病（COPD）的药物。在之前的一项研究中，系统药理学确定了BJF的145种活性化合物和175个潜在靶点。此外，先前研究表明BJF在体内可通过抑制炎性细胞因子产生、基质金属蛋白酶表达及其他细胞因子产生，有效预防COPD及其合并症，如心室肥厚。然而，BJF治疗COPD的系统水平机制仍不清楚。本研究的目的是通过整合转录组学、蛋白质组学和代谢组学以及系统药理学数据集，深入了解其系统水平机制。通过分子功能、通路和网络分析，COPD大鼠和BJF治疗大鼠中受调控的基因和蛋白质主要归因于氧化还原酶活性、抗氧化活性、粘着斑、紧密连接或黏着连接。此外，还对系统药理学、转录本、蛋白质和代谢物数据集进行了综合分析。结果表明，BJF治疗大鼠中受调控的一些基因、蛋白质、代谢物以及BJF的潜在靶蛋白参与了脂质代谢、细胞连接、氧化应激和炎症反应，这可能是BJF治疗COPD的系统水平治疗机制。
Zotero 插件
